HPV16 Intratypic Variants in Head and Neck Cancers: A North American Perspective

Area of Science:

• Oncology
• Virology
• Genetics

Background:

• Human papillomavirus (HPV) is a primary cause of cervical and head and neck cancers (HNCs).
• HPV genetic variation, specifically single nucleotide polymorphisms (SNPs), defines intratypic variants.
• While HPV16 variants are studied in cervical cancer, their role in HNC is less understood.

Purpose of the Study:

• To investigate the distribution and clinical impact of HPV16 intratypic variants in North American HNC cases.
• To determine if specific HPV16 variants are associated with differences in cancer staging, survival, or immune response.

Main Methods:

• Combined HPV16-positive HNC samples from Ontario and The Cancer Genome Atlas (TCGA) for a total of 149 cases.
• Classified HPV16 variants based on L1 region SNPs, focusing on the T350G polymorphism in the E6 gene.
• Performed univariable and multivariable analyses to assess associations between variants and clinical outcomes, including staging, disease-free survival, and immune markers.

Main Results:

• Most HPV16 isolates belonged to lineage A, sublineages A1 or A2.
• Significant differences were observed between T350G and 350T variants in clinical T, N, and O staging, and disease-free survival (univariable analysis).
• Differences in B-cell mediated immune responses were noted between the T350G and 350T variants.

Conclusions:

• HPV16 intratypic variants, particularly the T350G polymorphism, are associated with HNC clinical characteristics.
• HPV genetic variation may hold prognostic value for head and neck cancer patients.
• Further research is warranted to explore the mechanisms underlying these associations and their clinical implications.